AMAmarendar Reddy M.

Amarendar Reddy M.

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amarendar Reddy M. has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Punam Salaria

    Department of Chemistry, School of Sciences, National Institute of Technology Andhra Pradesh, Tadepalligudem, Andhra Pradesh, 534101, India; Department of Chemistry, Indian Institute of Technology Kharagpur, West Bengal, 721302, India

    10 shared publications
  • Desu Gayathri Niharika

    Department of Chemistry, School of Sciences, National Institute of Technology Andhra Pradesh, Tadepalligudem, Andhra Pradesh, 534101, India

    5 shared publications
  • P. Lakshmi Ganapati

    Department of Chemistry, Sasi Institute of Engineering & Technology, Tadepalligudem, Andhra Pradesh, 534101, India

    2 shared publications
  • Tejas M. Dhameliya

    Department of Pharmaceutical Chemistry Institute of Pharmacy Nirma University Ahmedabad Gujarat 382 481 India

    2 shared publications
  • Vivek Kumar Vyas

    Department of Pharmaceutical Chemistry Institute of Pharmacy Nirma University Ahmedabad Gujarat 382 481 India

    2 shared publications
  • Aasheesh Srivastava

    Department of Chemistry, Indian Institute of Science Education and Research Bhopal (IISER Bhopal), Bhauri, Bhopal Bypass Road, Bhopal, 462 066, Madhya Pradesh, India

    1 shared publication

Latest Publications

  • Integrated machine learning and computational approaches for identifying NLRP3 inhibitors from Jeevaneeya Rasayana in epilepsy

    by Desu Gayathri Niharika, Punam Salaria, Abothula Anusha, P. Lakshmi Ganapati, M. Amarendar Reddy

  • Unveiling Molecular Mechanisms and Salient Targets in Phthalates‐Induced Neurodevelopmental Disorders Through Comprehensive Network Toxicology and Molecular Docking Strategy

    by Desu Gayathri Niharika, Punam Salaria, Amarendar Reddy M.

    Phthalates are well‐known emerging contaminants in the environment and food packaging, posing serious risks to human health as endocrine disruptors with significant neurotoxic potential. Epidemiological and experimental evidence have linked early‐life phthalate exposure to neurodevelopmental disorders, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). However, the precise molecular mechanisms responsible for these associations remain poorly understood. This study aimed to comprehensively investigate the putative toxic targets and molecular pathways underlying phthalate‐induced ADHD and ASD through integrated network toxicology and molecular docking approaches. Targets related to phthalates, ADHD, and ASD were extracted from various databases, yielding 21 potential targets associated with ADHD and ASD, which are common to the studied phthalates. Network analysis highlighted BDNF and ESR1 as the top two core targets. Functional enrichment analyses demonstrated that the core targets are involved in multiple pathways. Furthermore, the GEO database was queried to identify differentially expressed genes (DEGs) and gene modules through Weighted Gene Co‐expression Network Analysis (WGCNA) using the R package. Moreover, molecular docking demonstrated high binding affinity between phthalates and core targets, with di(2‐ethylhexyl) phthalate with BDNF and diisononyl phthalate with ESR1, emphasizing the potential role of phthalate exposure in neurodevelopmental disorders. The stability of these complexes was demonstrated through molecular dynamics simulations, which confirmed their binding interactions remained constant throughout the simulation. Our findings contribute to a deeper understanding of the intricate molecular mechanisms of phthalate‐induced neurotoxicity, offering a valuable foundation for the development of future therapeutic strategies to mitigate their adverse effects on neurodevelopment.


  • Investigations Through In Silico Molecular Modelling Against Falcipain‐2 in Search of Potent Anti‐Malarial Agents

    by Vidhisha N. Savaliya, Priyansh Rastogi, Prit D. Savaliya, Punam Salaria, Amarendar Reddy M., Vivek K. Vyas, Gopal Natesan, Tejas M. Dhameliya

    Malaria remains a major global health concern, exacerbated by the increasing resistance of Plasmodium falciparum to existing anti‐malarial drugs. This growing challenge necessitates the urgent discovery of novel therapeutic agents targeting unexplored biological pathways. Falcipain‐2, a cysteine protease involved in hemoglobin metabolism during the erythrocytic stage, has emerged as the promising and key drug target. The current state of resistance to malaria treatments has made it imperative to find new anti‐malarial drugs using in silico tools driven by computer aided drug design. A virtual screening of 91,001 ligands from the Asinex Elite Synergy 2021–02 library has been performed using AutoDock Vina, yielding 20 hits with superior binding affinities (−10.0 to −9.7 kcal/mol) compared to the reference inhibitor, E64 (−5.8 kcal/mol). Further evaluation of their pharmacokinetic and toxicity profiles confirmed their favorable ADMET properties, suggesting high oral bioavailability and drug‐likeness. The stability of the top two identified compounds in complex with Falcipain‐2 was further validated through molecular dynamics (MD) simulations over 100 ns using GROMACS. These findings highlight the efficacy of computational strategies in accelerating anti‐malarial drug discovery and provide a strong foundation for the development of next‐generation therapeutics targeting drug‐resistant malaria.


  • Unraveling potent Glycyrrhiza glabra flavonoids as AKT1 inhibitors using network pharmacology and machine learning-assisted QSAR

    by Desu Gayathri Niharika, Punam Salaria, Amarendar Reddy M.

    Glycyrrhiza glabra (G. glabra) phytocompounds have been reported to interact with neurological targets, including those implicated in epilepsy, and may modulate epilepsy-related targets. While substantial evidence supports their potential antiepileptic effects, the underlying molecular mechanisms remain unclear. This study aims to elucidate the molecular mechanism of G. glabra phytocompounds by integrating network pharmacology and machine learning (ML)-based quantitative structure–activity relationship (QSAR) techniques. Network pharmacology analysis identified AKT1 as a key epilepsy-related target, and four ML-based 2D-QSAR models were developed using AKT1 inhibitors. The developed models underwent comprehensive validation, including internal and external validation, Y-randomization, statistical analysis, and applicability domain assessment to ensure robustness and reliability. Among them, the Multilayer Perceptron (MLP) model excelled as the most robust and demonstrated superior predictive ability with a correlation coefficient r2training = 0.95, r2test = 0.84, and cross-validation coefficient q2 = 0.72. The MLP model accurately predicted pIC50 values of phytoflavonoids, leading to the identification of 19 active molecules through the activity atlas model. ADME and drug-likeliness screening narrowed the selection to eleven promising compounds for further docking analysis. Molecular docking highlighted glabranin and 3’-hydroxy-4’-O-methylglabridin as top lead compounds with a binding energy of − 5.75 and − 5.37 kcal/mol, respectively. Additionally, 400 ns molecular dynamics simulation confirmed the structural and conformational stability of the glabranin-AKT1 complex, further reinforced by Principal Component Analysis, free energy landscapes, and Molecular Mechanics Poisson-Boltzmann/Generalized Born Surface Area. Collectively, these findings underscore the potential of G. glabra phytocompounds as promising antiepileptic candidates, paving the way for future advancements in this field. Graphical Abstract


  • Integrated computational approaches for identification of potent pyrazole-based glycogen synthase kinase-3β (GSK-3β) inhibitors: 3D-QSAR, virtual screening, docking, MM/GBSA, EC, MD simulation studies

    by Desu Gayathri Niharika, Punam Salaria, M. Amarendar Reddy

    Glycogen synthase kinase-3β (GSK-3β) has emerged as a crucial target due to its substantial contribution in various cellular processes. Dysfunctional GSK-3β activity can lead to ion channel disturbances, sustain abnormal excitability, and contribute to the pathogenesis of epilepsy and other GSK-3β-related disorders. A set of 82 pyrazole analogs was utilized to study its structural features using a three-dimensional quantitative structure–activity relationship (3D-QSAR), virtual screening, molecular docking, and molecular dynamics. The QSAR model, validated using internal and external methods, demonstrated robustness with a high correlation coefficient r2training = 0.99, cross-validation coefficient q2 = 0.79, r2test = 0.69, and r2external = 0.74. The “Average of Actives” in the Activity Atlas model identified 17 molecules as active. Subsequent pharmacophore-based virtual screening of 17 actives yielded 70 compounds, which were selected as the prediction set to determine the potential GSK-3β inhibitors. Docking studies pinpointed compound P66 as the promising lead compound, with a docking score of − 10.555 kcal/mol. These findings were further supported by electrostatic potential (ESP), electrostatic complementarity (EC), and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) analyses. Furthermore, a 500 ns molecular dynamics (MD) simulation confirmed the structural and conformational stability of the lead complex throughout the simulation period. As a result, this study suggests that compound P66 holds the potential to be a potent lead candidate for the inhibition of GSK-3β, offering a novel therapeutic approach for GSK-3β related disorders, including epilepsy. Graphical abstract


  • Deciphering the 4′,7‐Dihydroxy‐3′‐Methylflavone from Boerhavia , Agonist/Antagonist Interactions Against 5‐HT 2 Receptors using Homology Modeling, Molecular Docking, and Dynamic Simulation Studies

    by Punam Salaria, Desu Gayathri Niharika, Subrahmanyeswara Rao N. N., P. Lakshmi Ganapati, Amarendar Reddy M.

    Seizures, depression, and anxiety are neurological disorders that affected innumerable people worldwide. Recent research has revealed that targeting 5‐hydroxytryptamine 2 (5‐HT 2 ) receptors can help suppress these conditions. An in‐depth literature study has identified that phytocompounds from the Boerhavia genus could reduce seizures. Therefore, homology models of 5‐HT 2 receptors were generated and validated using techniques such as the alignment of amino acid sequences and the Ramachandran plot. Later, a comparison of modeled structures was made with a non‐redundant set of PDB structures. The pharmacokinetics, drug‐likeness, blood‐brain barrier (BBB) permeability, and Lipinski's rule of five shed light on 22 phytocompounds, which are the potential candidates for molecular docking among 127 Boerhavia's bioactive. Notably, molecular docking analysis revealed 4′,7‐dihydroxy‐3′‐methylflavone as the most potent lead compound, which has a strong binding affinity to all modeled receptors. Additionally, with a remarkably high docking score of −9.1 kcal/mol, 4′,7‐dihydroxy‐3′‐methylflavone showed promising interactions, particularly with 5‐HT 2A receptor, as seen from the RMSD, SASA, Rg, and number of hydrogen bonds during 100 ns molecular dynamic (MD) simulation. Principal component analysis (PCA) and Molecular Mechanics‐Poisson‐Boltzmann Surface Area (MM‐PBSA) further confirmed that 4′,7‐dihydroxy‐3′‐methylflavone is the best novel phytocompound in Boerhavia genus for 5‐HT 2 receptor as agonist/antagonist activity against seizures.


  • Investigation on Anti‐plasmodial Agents Against wild‐type Pf DHFR Through In Silico Computational Tools

    by Rajsi V. Parikh, Disha V. Pandya, Punam Salaria, Amarendar Reddy M., Vivek K. Vyas, Hardik G. Bhatt, Tejas M. Dhameliya

    Malaria is the most severe and common parasitic infection, with P. falciparum responsible for the majority of cases and deaths each year. As anti‐malarial drug resistance continues to increase, novel compounds with anti‐ P. falciparum activity must be identified. In search of a new molecule to cure the resistant malarial parasite, a total of 1,70,269 ligands from the Asinex BioDesign library 2021.2 were virtually screened using AutoDock Vina against wild‐type P. falciparum dihydrofolate reductase‐thymidylate synthase ( Pf DHFR‐TS). The computational molecular modeling investigations indicated the discovery of seventeen new compounds ( 2 ‐ 18 ) with higher binding energy compared to the Pf DHFR‐TS inhibitor, pyrimethamine ( 1 ). Furthermore, the study employing drug‐likeness criteria and their ADMET profile suggested that these hits were the most promising drug candidates due to higher absorption and druggability. Furthermore, GROMACS 2023.4 was used to perform the molecular dynamics simulations on the foremost compound ( 2 ) having sufficient stability, leading to a key step towards the search of novel Pf DHFR‐TS inhibitors against malaria.


  • Network Pharmacology Approach to Identify the Calotropis Phytoconstituents’ Potential Epileptic Targets and Evaluation of Molecular Docking, MD Simulation, and MM‐PBSA Performance

    by Punam Salaria, Amarendar Reddy M

    Epilepsy originates from unusual electrical rhythm within brain cells, causes seizures. Calotropis species have been utilized to treat a wide spectrum of ailments since antiquity. Despite chemical and biological investigations, there have been minimal studies on their anticonvulsant activity, and the molecular targets of this plant constituents are unexplored. This study aimed to investigate the plausible epileptic targets of Calotropis phytoconstituents through network pharmacology, and to evaluate their binding strength and stability with the identified targets. In detail, 125 phytoconstituents of the Calotropis plant (C. procera and C. gigantea) were assessed for their drug‐likeness (DL), blood‐brain‐barrier (BBB) permeability and oral bioavailability (OB). Network analysis revealed that targets PTGS2 and PPAR‐γ were ranked first and fourth, respectively, among the top ten hub genes significantly linked with antiepileptic drug targets. Additionally, docking, molecular dynamic (MD) simulation, and Molecular Mechanics‐Poisson‐Boltzmann Surface Area (MM‐PBSA) were employed to validate the compound‐gene interactions. Docking studies suggested ergost‐5‐en‐3‐ol, stigmasterol and β‐sitosterol exhibit stronger binding affinity and favorable interactions than co‐crystallized ligands with both the targets. Furthermore, both MD simulations and MM‐PBSA calculations substantiated the docking results. Combined data revealed that Calotropis phytoconstituents ergost‐5‐en‐3‐ol, stigmasterol, and β‐sitosterol might be the best inhibitors of both PTGS2 and PPAR‐γ.